IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 5, 2008, Pages 711-717

  Wang, J ^a   Yang, J W ^b   Zeevi, A ^c   Webber, S A ^c   Girnita, D M ^c   Selby, R ^d   Fu, J ^a   Shah, T ^b   Pravica, V ^a,b   Hutchinson, I V ^a,b,d   Burckart, G J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b National Institute of Transplantation Los Angeles   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; INOSINATE DEHYDROGENASE; INOSINE 5' MONOPHOSPHATE DEHYDROGENASE 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ALLELE; ARTICLE; DNA FLANKING REGION; DNA SEQUENCE; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; ALLELES; FEMALE; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 42349115968     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100347     Document Type: Article

References (42)

1. Allison, A.C. & Eugui, E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47, 85-118 (2000).
2. Meriggioli, M.N., Rowin, J., Richman, J.G. & Leurgans, S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann. NY Acad. Sci. 998, 494-499 (2003).
3. Provan, D., Moss, A.J., Newland, A.C. & Bussel, J.B. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am. J. Hematol. 81, 19-25 (2006).
4. Ginzler, E.M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219-2228 (2005).
5. Millan, O. et al. Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. Clin. Pharmacokinet. 44, 525-538 (2005).
6. Sankatsing, S.U. et al. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin. Pharmacokinet. 43, 823-832 (2004).
7. Fulton, B. & Markham, A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51, 278-298 (1996).
8. Zaza, G. et al. Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood 104, 1435-1441 (2004).
9. Carr, S.F., Papp, E., Wu, J.C. & Natsumeda, Y. Characterization of human type I and type II IMP dehydrogenases. J. Biol. Chem. 268, 27286-27290 (1993).
10. Zimmermann, A.G., Wright, K.L., Ting, J.P. & Mitchell, B.S. Regulation of inosine-5′-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5′ palindromic octamer sequence. J. Biol. Chem. 272, 22913-22923 (1997).
11. Sanquer, S., Breil, M., Baron, C., Dhamane, D., Astier, A. & Lang, P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin. Pharmacol. Ther. 65, 640-648 (1999).
12. Hager, P.W. et al. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem. Pharmacol. 49, 1323-1329 (1995).
13. Gu, J.J. et al. Targeted disruption of the inosine 5′-monophosphate dehydrogenase type I gene in mice. Mol. Cell. Biol. 23, 6702-6712 (2003).
14. Jain, J. et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem. Pharmacol. 67, 767-776 (2004).
15. Futer, O. et al. A mutational analysis of the active site of human type II inosine 5′-monophosphate dehydrogenase. Biochim. Biophys. Acta 1594, 27-39 (2002).
16. Digits, J.A. & Hedstrom, L. Species-specific inhibition of inosine 5′-monophosphate dehydrogenase by mycophenolic acid. Biochemistry 38, 15388-15397 (1999).
17. McPhillips, C.C., Hyle, J.W. & Reines, D. Detection of the mycophenolate-inhibited form of IMP dehydrogenase in vivo. Proc. Natl. Acad. Sci. USA 101, 12171-12176 (2004).
18. Bowne, S.J. et al. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 11, 559-568 (2002).
19. Bowne, S.J. et al. Why do mutations in the ubiquitously expressed housekeeping gene IMPDH1 cause retina-specific photoreceptor degeneration? Invest. Ophthalmol. Vis. Sci. 47, 3754-3765 (2006).
20. van Gelder, T. & Shaw, L.M. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 80, S244-S253 (2005).
21. Hale, M.D. et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin. Pharmacol. Ther. 64, 672-683 (1998).
22. Kelly, P. & Kahan, B.D. Review: metabolism of immunosuppressant drugs. Curr. Drug Metab. 3, 275-287 (2002).
23. Glander, P. et al. Non-radioactive determination of inosine 5′-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin. Biochem. 34, 543-549 (2001).
24. Glander, P. et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant. 4, 2045-2051 (2004).
25. Wilkinson, A. Progress in the clinical application of immunosuppressive drugs in renal transplantation. Curr. Opin. Nephrol. Hypertens. 10, 763-770 (2001).
26. Moreso, F. et al. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin. Transplant. 12, 198-205 (1998).
27. Wang, J. et al. A novel variant L263F in human inosine 50-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet. Genomics 17, 283-290 (2007).
28. Zheng, H.X. et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transplant. Immunol. 14, 37-42 (2005).
29. Bernard, O., Tojcic, J., Journault, K., Perusse, L. & Guillemette, C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab. Dispos. 34, 1539-1545 (2006).
30. Girard, H. et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14, 501-515 (2004).
31. Kuypers, D.R., Naesens, M., Vermeire, S. & Vanrenterghem, Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther. 78, 351-361 (2005).
32. Naesens, M., Kuypers, D.R., Verbeke, K. & Vanrenterghem, Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82, 1074-1084 (2006).
33. Staatz, C.E. & Tett, S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin. Pharmacokinet. 46, 13-58 (2007).
34. Kennan, A. et al. Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. Hum. Mol. Genet. 11, 547-557 (2002).
35. Bowne, S.J. et al. Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and Leber congenital amaurosis. Invest. Ophthalmol. Vis. Sci. 47, 34-42 (2006).
36. Roberts, R.L., Gearry, R.B., Barclay, M.L. & Kennedy, M.A. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J. doi:10.1038/sj.tpj.6500421 (2006).
37. Press, R. et al. Race/ethnicity, poverty status, and renal transplant outcomes. Transplantation 80, 917-924 (2005).
38. Brennan, D.C. et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med. 355, 1967-1977 (2006).
39. Meier-Kriesche, H.U. et al. The effect of daclizumab in a high-risk renal transplant population. Clin. Transplant. 14, 509-513 (2000).
40. Ciancio, G. et al. The use of daclizumab, tacrolimus and mycophenolate mofetil in African-American and Hispanic first renal transplant recipients. Am. J. Transplant. 3, 1010-1016 (2003).
41. Burckart, G.J., Hutchinson, I.V. & Zeevi, A. Pharmacogenomics and lung transplantation: clinical implications. Pharmacogenomics J. 6, 301-310 (2006).
42. Green, S. & Weiss, G.R. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs 10, 239-253 (1992).